Nanjing Immunophage Biotech Co., Ltd
Clinical trials sponsored by Nanjing Immunophage Biotech Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug IPG1094 gets first human test in china Results expected Jan 2027 (estimated)
- New pill shows promise in early trial for Hard-to-Treat cancers Results expected Jul 2027 (estimated)
-
Experimental cancer combo enters early human testing
Disease control Recruiting nowThis early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…
Phase 1/2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called IPG1094 in 60 people with advanced solid tumors that cannot be removed by surgery. The drug works by blocking a protein called MIF, which may help slow cancer growth. The trial has two parts: first, finding the safest dose, then seeing if the dr…
Phase 1/2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug IPG1094 gets first human test in china
Knowledge-focused Recruiting nowThis phase 1 trial tests the drug IPG1094 in 24 healthy Chinese adults to understand how the body absorbs, processes, and eliminates it. Part A examines whether food affects a single dose, while Part B looks at repeated dosing over 10 days. All participants are monitored for safe…
Phase 1 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC